newsfilter
← Latest News
GlobeNewswire·

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer, during an oral presentation at the 2025 Annual Meeting of the